3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
2
Pancreatic Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoid Tumor
1
Adenoma, Islet Cell
1
Interventions
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Sunitinib
2
Everolimus
2
sargramostim
1
montanide ISA 51
1
lutetium Lu 177 dotatate
1
lanreotide
1
incomplete Freund's adjuvant
1
fludarabine phosphate
1
cabozantinib
1
belzutifan
1
X-Rays
1
Temozolomide
1
Phantoms, Imaging
1
Octreotide
1
Methods
1
Interleukin-13
1
Fluorodeoxyglucose F18
1
Cyclophosphamide
1
Colony-Stimulating Factors
1
Blood Specimen Collection
1
Biopsy
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoma, Islet Cell
×
lanreotide
×
90 days
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled